On the contrary, a study has shown that TP53 and K-Ras co-mutations in lung adenocarcinoma correlate with the expression of PD-L1 on tumors for immune escape, and it has indicated substantial clinical benefits of PD-1 inhibitors in treating patients with these two genetic mutations [71]. Here, TP53 is linked to lung adenocarcinoma.